Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $106.20

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a consensus rating of “Hold” from the twenty-two ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $106.20.

Several brokerages recently commented on ZBH. The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a report on Friday, January 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $94.00 to $120.00 in a research report on Monday, January 5th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th.

Zimmer Biomet Stock Down 1.6%

Shares of ZBH opened at $91.78 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. Zimmer Biomet has a 12 month low of $84.59 and a 12 month high of $114.44. The stock’s 50 day moving average is $92.21 and its two-hundred day moving average is $95.41. The firm has a market cap of $17.96 billion, a P/E ratio of 25.93, a PEG ratio of 1.91 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the prior year, the company posted $2.31 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Institutional Trading of Zimmer Biomet

Institutional investors have recently made changes to their positions in the company. Advisortrust Partners LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $442,000. Corient Private Wealth LLC lifted its holdings in Zimmer Biomet by 11.5% in the 4th quarter. Corient Private Wealth LLC now owns 46,989 shares of the medical equipment provider’s stock valued at $4,230,000 after purchasing an additional 4,863 shares in the last quarter. Auto Owners Insurance Co boosted its stake in Zimmer Biomet by 8,892.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after purchasing an additional 1,987,362 shares during the last quarter. Pacer Advisors Inc. boosted its stake in Zimmer Biomet by 4,020.2% during the 4th quarter. Pacer Advisors Inc. now owns 697,753 shares of the medical equipment provider’s stock worth $62,742,000 after purchasing an additional 680,818 shares during the last quarter. Finally, Monetary Solutions Ltd purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth $30,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.